Targeting and lysing microthrombi associated with aberrant blood clotting
OwnerSteven DE MAAT, Coen MAASinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides means and methods for treating MVT and associated and/or similar conditions. The invention therefore provides hybrid proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The invention further provides therapeutic methods for conditions that can be prevented or treated by local delivery/stimulation of plasminogen activation to sites of microvascular occlusion.
Claims29
A polypeptide comprising a urokinase catalytic domain, wherein the arginine residue corresponding to position 153 in SEQ ID No. 1 is substituted with a glutamine residue.
5-6. (canceled)
A hybrid protein comprising a polypeptide comprising a urokinase catalytic domain, wherein an arginine residue corresponding to position 153 in SEQ ID No. 1 is substituted with a glutamine residue;
- wherein position 299 in SEQ ID No. 1 is an asparagine residue or a histidine residue;
- and
- wherein the hybrid protein comprises an VHH .
(canceled)
11-13. (canceled)
17-18. (canceled)
(canceled)
22-23. (canceled)
(canceled)
30-32. (canceled)
(canceled)
Dependencies are inferred from the claim text.